Skip to main content
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive164AccountSocial
MARKETSINVESTLIVE164
Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
Series Image
  1. Medicine

Will the FDA approve retatrutide?



AI Digest · Eli Lilly's retatrutide knee pain results meet traders weighing FDA approval before 2028

Not advice · 16h ago
Chance

9%
▲ 4

9%
▲ 4

70%
▲ 14

70%
▲ 14

91%
▲ 6

91%
▲ 6

2 more

Will the FDA approve retatrutide?

Before Jan 1, 2027

Odds
2% chance
Max payout
Dec 31, 2026
$0
$119,042 vol
More Science and Technology Markets

Trending Science and Technology markets

Will the U.S. confirm that aliens exist?Best AI at the end of 2026?What kind of device will Jony Ive and OpenAI announce?Where will Waymo operate this year?Which AI will be the first to hit 1550 on Text Arena?SpaceX Starship 16th launch?Open vs. Closed Token Volume (open weights share) todayWhich countries will report an Ebola case this year?

Science and Technology hub

All Science and Technology markets